目的:探究叶酸受体(Folate receptor alpha, FR-α)蛋白联合消除速率常数K (the modeled CA125 ELIMination rate constant K, KELIM)在预测晚期卵巢高级别浆液性腺癌(ovarian high-grade serous adenocarcinoma, HGCS)铂类药物化疗后...目的:探究叶酸受体(Folate receptor alpha, FR-α)蛋白联合消除速率常数K (the modeled CA125 ELIMination rate constant K, KELIM)在预测晚期卵巢高级别浆液性腺癌(ovarian high-grade serous adenocarcinoma, HGCS)铂类药物化疗后铂耐药复发中的应用。方法:收集行满意肿瘤细胞减灭术,以术后联合铂类为基础,规范化疗的40例患者,根据患者停止化疗后6个月复发情况,分为铂敏感复发组和铂耐药复发组(各20例),分析总结HGCS铂耐药的因素。结果:FR-α在HGCS中高表达,阳性率为75%;两组患者年龄、BMI、术前CA125等一般资料比较差异无统计学意义(P > 0.05),KELIM评分、FR-α、ROMA比较差异具有统计学意义(P α是晚期卵巢高级别浆液性腺癌铂耐药复发独立的预后因素(OR:0.181,95%CI:0.033~0.982,P = 0.048;OR:0.030,95%CI:0.002~0.475,P = 0.013);将Logistic多因素分析有意义的指标,绘制ROC曲线,结果:FR-α联合KELIM评分曲线下面积为0.818 (95%CI:0.683~0.952,P = 0.001),灵敏度为0.80%。结论:FR-α在HGCS中高表达,FR-α、KELIM值是HGCS铂耐药复发独立的预后因素,二者联合检测对HGCS铂类耐复发具有一定预测价值。Objective: To explore the application of folate receptor alpha (FR-α) protein combined with the modeled CA125 ELIMination rate constant K (KELIM) in predicting platinum-resistant recurrence after platinum-based chemotherapy in advanced ovarian high-grade serous adenocarcinoma (HGCS). Methods: Forty patients who underwent satisfactory tumor cytoreductive surgery and postoperative platinum-based chemotherapy were collected. According to the recurrence of patients 6 months after chemotherapy, they were divided into platinum-sensitive recurrence group and platinum-resistant recurrence group (20 cases each). The factors of platinum resistance in HGCS were analyzed and summarized. Results: FR-α was highly expressed in HGCS, with a positive rate of 75%. There was no significant difference in age, BMI, preoperative CA125 and other general data between the two groups (P > 0.05). There were significant differences in KELIM score, FR-α and ROMA between the two groups (P α were independent prognostic factors for platinum-resistant recurrence of advanced ovarian high-grade serous adenocarcinoma (OR: 0.181, 95%CI: 0.033~0.982, P = 0.048;OR: 0.030, 95%CI: 0.002~0.475, P = 0.013);logistic multivariate analysis was used to analyze the meaningful indicators, and the ROC curve was drawn. Results: The area under the curve of FR-α combined with KELIM score was 0.818 (95%CI: 0.683~0.952, P = 0.001), and the sensitivity was 0.80%. Conclusion: FR-α is highly expressed in HGCS. FR-α and KELIM values are independent prognostic factors for platinum-resistant recurrence of HGCS. The combined detection of the two has a certain predictive value for platinum-resistant recurrence of HGCS.展开更多
目的探究核受体结合SET结构域蛋白2(Nuclear receptor-binding SET domain-containing protein 2,NSD2)在胃癌(gastric cancer,GC)中的表达模式及其对胃癌细胞生物学行为、顺铂耐药及肿瘤免疫的影响。方法生物信息学分析胃癌中NSD2表达...目的探究核受体结合SET结构域蛋白2(Nuclear receptor-binding SET domain-containing protein 2,NSD2)在胃癌(gastric cancer,GC)中的表达模式及其对胃癌细胞生物学行为、顺铂耐药及肿瘤免疫的影响。方法生物信息学分析胃癌中NSD2表达量及对预后、胃癌免疫细胞及免疫因子的影响;RT-qPCR检测胃及胃癌细胞系中NSD2表达量;使用NSD2抑制剂(LEM-14、UNC6934)建立NSD2低表达胃癌细胞模型,Western Blot检测细胞系NSD2抑制效率;CCK-8、克隆形成实验和划痕愈合实验测NSD2表达对胃癌细胞的增殖及迁移能力的影响;CCK-8实验检测NSD2对顺铂耐药的影响。结果GEPIA2数据库/UALCNA网站分析结果显示,NSD2在胃癌组织中表达高于癌旁组织(P<0.05);Kaplan-Meier Plotter结果提示NSD2低表达的胃癌患者有较好的预后(P<0.05);抑制NSD2表达后胃癌细胞的增殖及迁移能力受到显著抑制(P<0.05);NSD2的表达促进胃癌细胞系顺铂(HGC-27)耐药(P<0.05),提高顺铂IC50(P<0.001);TISDIB分析提示NSD2抑制CD4及CD8免疫细胞浸润,与PD-L1、CTLA4表达呈正相关。结论NSD2在胃癌组织和细胞系中高表达,高表达的胃癌患者预后较差;NSD2促进胃癌细胞增殖及迁移能力、顺铂耐药及增加顺铂IC50、促进胃癌细胞免疫逃逸。展开更多
目的构建预测上皮性卵巢癌(epithelial ovarian cancer,EOC)铂耐药复发的风险模型。方法回顾性分析2012年1月1日至2022年6月30日在云南省肿瘤医院行手术治疗的1392例EOC患者的临床病理资料。对可能影响铂耐药复发的16个因素进行单因素...目的构建预测上皮性卵巢癌(epithelial ovarian cancer,EOC)铂耐药复发的风险模型。方法回顾性分析2012年1月1日至2022年6月30日在云南省肿瘤医院行手术治疗的1392例EOC患者的临床病理资料。对可能影响铂耐药复发的16个因素进行单因素和多因素logistic回归分析并构建logistic回归预测模型。采用加强Bootstrap法对模型进行内部验证。模型表现通过受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)、敏感度、特异度和Brier得分评价,并将模型可视化为列线图和网页计算器。结果多因素logistic回归分析显示,血清乳酸脱氢酶水平、国际妇产科联合会(International Federation of Gynecology and Obstetrics,FIGO)分期、术后化疗周期和血小板计数均是影响EOC铂耐药复发的独立影响因素(均P<0.05)。基于年龄和上述变量构建的logistic回归模型的AUC、敏感度和特异度分别为0.704、62.0%和68.4%。模型在内部验证中的Brier得分为0.002。结论基于乳酸脱氢酶开发的预测EOC患者铂耐药复发的列线图可用于指导临床实践。展开更多
文摘目的:探究叶酸受体(Folate receptor alpha, FR-α)蛋白联合消除速率常数K (the modeled CA125 ELIMination rate constant K, KELIM)在预测晚期卵巢高级别浆液性腺癌(ovarian high-grade serous adenocarcinoma, HGCS)铂类药物化疗后铂耐药复发中的应用。方法:收集行满意肿瘤细胞减灭术,以术后联合铂类为基础,规范化疗的40例患者,根据患者停止化疗后6个月复发情况,分为铂敏感复发组和铂耐药复发组(各20例),分析总结HGCS铂耐药的因素。结果:FR-α在HGCS中高表达,阳性率为75%;两组患者年龄、BMI、术前CA125等一般资料比较差异无统计学意义(P > 0.05),KELIM评分、FR-α、ROMA比较差异具有统计学意义(P α是晚期卵巢高级别浆液性腺癌铂耐药复发独立的预后因素(OR:0.181,95%CI:0.033~0.982,P = 0.048;OR:0.030,95%CI:0.002~0.475,P = 0.013);将Logistic多因素分析有意义的指标,绘制ROC曲线,结果:FR-α联合KELIM评分曲线下面积为0.818 (95%CI:0.683~0.952,P = 0.001),灵敏度为0.80%。结论:FR-α在HGCS中高表达,FR-α、KELIM值是HGCS铂耐药复发独立的预后因素,二者联合检测对HGCS铂类耐复发具有一定预测价值。Objective: To explore the application of folate receptor alpha (FR-α) protein combined with the modeled CA125 ELIMination rate constant K (KELIM) in predicting platinum-resistant recurrence after platinum-based chemotherapy in advanced ovarian high-grade serous adenocarcinoma (HGCS). Methods: Forty patients who underwent satisfactory tumor cytoreductive surgery and postoperative platinum-based chemotherapy were collected. According to the recurrence of patients 6 months after chemotherapy, they were divided into platinum-sensitive recurrence group and platinum-resistant recurrence group (20 cases each). The factors of platinum resistance in HGCS were analyzed and summarized. Results: FR-α was highly expressed in HGCS, with a positive rate of 75%. There was no significant difference in age, BMI, preoperative CA125 and other general data between the two groups (P > 0.05). There were significant differences in KELIM score, FR-α and ROMA between the two groups (P α were independent prognostic factors for platinum-resistant recurrence of advanced ovarian high-grade serous adenocarcinoma (OR: 0.181, 95%CI: 0.033~0.982, P = 0.048;OR: 0.030, 95%CI: 0.002~0.475, P = 0.013);logistic multivariate analysis was used to analyze the meaningful indicators, and the ROC curve was drawn. Results: The area under the curve of FR-α combined with KELIM score was 0.818 (95%CI: 0.683~0.952, P = 0.001), and the sensitivity was 0.80%. Conclusion: FR-α is highly expressed in HGCS. FR-α and KELIM values are independent prognostic factors for platinum-resistant recurrence of HGCS. The combined detection of the two has a certain predictive value for platinum-resistant recurrence of HGCS.
文摘目的探究核受体结合SET结构域蛋白2(Nuclear receptor-binding SET domain-containing protein 2,NSD2)在胃癌(gastric cancer,GC)中的表达模式及其对胃癌细胞生物学行为、顺铂耐药及肿瘤免疫的影响。方法生物信息学分析胃癌中NSD2表达量及对预后、胃癌免疫细胞及免疫因子的影响;RT-qPCR检测胃及胃癌细胞系中NSD2表达量;使用NSD2抑制剂(LEM-14、UNC6934)建立NSD2低表达胃癌细胞模型,Western Blot检测细胞系NSD2抑制效率;CCK-8、克隆形成实验和划痕愈合实验测NSD2表达对胃癌细胞的增殖及迁移能力的影响;CCK-8实验检测NSD2对顺铂耐药的影响。结果GEPIA2数据库/UALCNA网站分析结果显示,NSD2在胃癌组织中表达高于癌旁组织(P<0.05);Kaplan-Meier Plotter结果提示NSD2低表达的胃癌患者有较好的预后(P<0.05);抑制NSD2表达后胃癌细胞的增殖及迁移能力受到显著抑制(P<0.05);NSD2的表达促进胃癌细胞系顺铂(HGC-27)耐药(P<0.05),提高顺铂IC50(P<0.001);TISDIB分析提示NSD2抑制CD4及CD8免疫细胞浸润,与PD-L1、CTLA4表达呈正相关。结论NSD2在胃癌组织和细胞系中高表达,高表达的胃癌患者预后较差;NSD2促进胃癌细胞增殖及迁移能力、顺铂耐药及增加顺铂IC50、促进胃癌细胞免疫逃逸。
文摘目的构建预测上皮性卵巢癌(epithelial ovarian cancer,EOC)铂耐药复发的风险模型。方法回顾性分析2012年1月1日至2022年6月30日在云南省肿瘤医院行手术治疗的1392例EOC患者的临床病理资料。对可能影响铂耐药复发的16个因素进行单因素和多因素logistic回归分析并构建logistic回归预测模型。采用加强Bootstrap法对模型进行内部验证。模型表现通过受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)、敏感度、特异度和Brier得分评价,并将模型可视化为列线图和网页计算器。结果多因素logistic回归分析显示,血清乳酸脱氢酶水平、国际妇产科联合会(International Federation of Gynecology and Obstetrics,FIGO)分期、术后化疗周期和血小板计数均是影响EOC铂耐药复发的独立影响因素(均P<0.05)。基于年龄和上述变量构建的logistic回归模型的AUC、敏感度和特异度分别为0.704、62.0%和68.4%。模型在内部验证中的Brier得分为0.002。结论基于乳酸脱氢酶开发的预测EOC患者铂耐药复发的列线图可用于指导临床实践。
